|
AU664360B2
(en)
|
1991-03-05 |
1995-11-16 |
Wellcome Foundation Limited, The |
Expression of recombinant proteins in attenuated bacteria
|
|
EP0897983B1
(en)
|
1991-10-25 |
2003-05-07 |
Immunex Corporation |
Antibody against CD40-L
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
WO1994005326A1
(en)
|
1992-09-04 |
1994-03-17 |
University Of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
ATE220331T1
(de)
|
1995-03-01 |
2002-07-15 |
Immunex Corp |
Cd40 bindendes protein zur stimulierung der immunantwort
|
|
DE69631331T2
(de)
|
1995-06-07 |
2004-11-18 |
Immunex Corp., Seattle |
Cd40l mutein
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
AU2004199A
(en)
|
1997-12-19 |
1999-07-12 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
EP1970449B1
(en)
|
1998-09-04 |
2010-11-03 |
Emergent Product Development UK Limited |
Attenuated salmonella SPI2 mutants as antigen carriers
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
CA2369820A1
(en)
|
1999-04-16 |
2000-10-26 |
Frank Dicker |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
AU1084901A
(en)
|
1999-10-14 |
2001-04-23 |
Martha S. Hayden-Ledbetter |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
TR200401569T4
(tr)
|
1999-12-28 |
2004-07-21 |
Akzo Nobel N.V. |
Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
|
|
DE60136334D1
(en)
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
DK1267899T3
(da)
|
2000-03-17 |
2005-12-12 |
Pharmacia & Upjohn Co Llc |
ssa-inaktiverede salmonellavacciner
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US20030060410A1
(en)
|
2001-05-15 |
2003-03-27 |
North Shore Long Island Jewish Research Institute |
Use of HMG fragments as anti-inflammatory agents
|
|
EP2107110A3
(en)
|
2001-05-15 |
2011-10-26 |
Ortho-McNeil Pharmaceutical, Inc. |
Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
CA2470640A1
(en)
|
2001-12-19 |
2003-06-26 |
Alcedo Biotech Gmbh |
Use of hmgb proteins and nucleic acids that code therefor
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP1499191B1
(en)
|
2002-04-15 |
2012-05-09 |
Washington University in St. Louis |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20060121047A1
(en)
|
2002-11-20 |
2006-06-08 |
Tracey Kevin J |
Use of hmgb polypetides for increasing immune responses
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
JP2006510619A
(ja)
|
2002-11-20 |
2006-03-30 |
クリティカル セラピューティクス，インコーポレイテッド |
抗炎症剤としてのｈｍｇｂ断片の使用
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
WO2005058950A2
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005103073A2
(en)
|
2004-04-27 |
2005-11-03 |
Intercell Ag |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
*
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
EP1814576A2
(en)
|
2004-07-20 |
2007-08-08 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
CN101080487B
(zh)
|
2004-10-07 |
2012-11-14 |
阿戈斯治疗公司 |
成熟树突细胞组合物及其培养方法
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
NZ556004A
(en)
|
2004-12-21 |
2010-05-28 |
Vaxinnate Corp |
Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
EP1909834A2
(en)
|
2005-07-18 |
2008-04-16 |
Critical Therapeutics, Inc. |
Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
|
|
DE602006014720D1
(de)
|
2005-10-07 |
2010-07-15 |
Proyecto Biomedicina Cima Sl |
Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
|
|
JP2009514536A
(ja)
|
2005-11-07 |
2009-04-09 |
シドニー キンメル キャンサー センター |
Ｃｄ４０リガンド融合蛋白質ワクチン
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
*
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
AU2007345768B2
(en)
*
|
2006-07-27 |
2013-08-01 |
Ligocyte Pharmaceuticals, Inc. |
Chimeric influenza virus-like particles
|
|
US8564612B2
(en)
*
|
2006-08-04 |
2013-10-22 |
Apple Inc. |
Deep pixel pipeline
|
|
JP2010500034A
(ja)
|
2006-08-09 |
2010-01-07 |
メッドイミューン バクシーンズ，インコーポレイティド |
インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
|
|
CN101522210B
(zh)
|
2006-09-18 |
2017-03-22 |
阿肯色大学评议会 |
增强免疫应答的组合物和方法
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CA2688548A1
(en)
*
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
WO2009059018A1
(en)
|
2007-10-30 |
2009-05-07 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
EP3097926B1
(en)
|
2007-11-01 |
2019-10-02 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses to eimeria
|
|
KR101638661B1
(ko)
|
2010-01-21 |
2016-07-11 |
더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 |
백신 벡터 및 면역 반응을 강화시키는 방법
|
|
PL2579901T3
(pl)
|
2010-06-09 |
2020-02-28 |
The Board Of Trustees Of The University Of Arkansas |
Szczepionka i sposoby ograniczania infekcji campylobacter
|
|
AU2012334962B2
(en)
|
2011-11-11 |
2017-02-16 |
Chr. Hansen A/S |
Lactic acid bacteria and their use as dietary supplementals for poultry
|